✨ Free AI Report
Eisai Co., Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Eisai Co., Ltd.
Company Research

Eisai Co., Ltd.: Business Overview, Financials & Competitive Analysis

Eisai is a Japanese pharmaceutical company focused on neurology and oncology that discovers, develops, manufactures and markets prescription medicines, OTC drugs and generics. Key products include LEQEMBI for early-st...

Analyst-debate audio for Eisai Co., Ltd.

AskCyborg analysts argue the bull and bear cases for Eisai Co., Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Eisai offers pharmaceutical exposure in neurology and oncology with marquee assets like LEQEMBI, but faces valuation headwinds...

Read the full analyst-debate transcript →
Industry Pharmaceuticals and Healthcare - Specialty & Generic Drug Manufacturing
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Eisai Co., Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Eisai Co., Ltd. Overview

Pro stress-test →

Eisai is a Japanese pharmaceutical company focused on neurology and oncology that discovers, develops, manufactures and markets prescription medicines, OTC drugs and generics. Key products include LEQEMBI for early-stage Alzheimer's disease, Lenvima for cancer treatment, and Dayvigo for insomnia.

Strategic Profile

Pro stress-test →

The vast majority of Eisai's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies to expand its research, development, manufacturing, and marketing capabilities. The stock trades at a trailing P/E of 31.8x, above the 15.4x average for the Japanese pharmaceuticals industry.

Competitive Landscape

Pro stress-test →

Eisai competes within the Drug Manufacturers—Specialty & Generic sector against peers like Takeda Pharmaceutical (market cap ¥7.8T). The company's focus on neurology and oncology puts it in competition with global pharmaceutical giants including Pfizer, Merck, and Bristol Myers Squibb. Eisai's differentiation centers on specialized therapeutic areas and licensing strategies.

Industry Context

Eisai Co., Ltd. operates in Pharmaceuticals and Healthcare - Specialty & Generic Drug Manufacturing.

Key facts

Founded: 1941 · Headquarters: Tokyo, Japan · Employees: 13,506 · Revenue: $5.06B · Market cap: $8.3B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Eisai Co., Ltd..

  • Net margin at 5.3% on ¥808.2b of revenue indicates vulnerability to drug pricing or competitive pressure
  • Trading at 31.8x P/E versus 20.8x for peer average reflects market optimism on future growth
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Q3 2026 revenue of ¥219.9 billion with ¥17,178 million net income shows quarterly strength
  • Aug 2025Strategic investment in Seed Therapeutics reflects ongoing biotech partnerships for innovation
  • +1 moreTrack every material event for Eisai Co., Ltd. as it happens. Explore monitoring →
Get alerted when Eisai Co., Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

TakedaLarger Japanese pharma with diversified portfolio→Bristol Myers SquibbStrategic oncology partner for Eisai→MerckOncology and neurology competitor→PfizerGlobal pharmaceutical leader with oncology focus→

Compare Eisai Co., Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Eisai Co., Ltd. operates in Pharmaceuticals and Healthcare - Specialty & Generic Drug Manufacturing. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals and Healthcare - Specialty & Generic Drug Manufacturing research →
NEW · MCP server

Ask your AI assistant about Eisai Co., Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Eisai Co., Ltd. and its top competitor on Cyborg Score”
“What did Eisai Co., Ltd. do this quarter?”
“Is Eisai Co., Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Eisai Co., Ltd. do?+
Eisai is a Japanese pharmaceutical company focused on neurology and oncology that discovers, develops, manufactures and markets prescription medicines, OTC drugs and generics. Key products include LEQEMBI for early-st...
What is Eisai Co., Ltd.'s Cyborg Score?+
Eisai Co., Ltd. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Eisai Co., Ltd.'s main competitors?+
Named competitors include Takeda, Bristol Myers Squibb, Merck, Pfizer. The full competitive landscape is in the AskCyborg report.
How can I get the full Eisai Co., Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Eisai Co., Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Eisai Co., Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals and Healthcare - Specialty & Generic Drug Manufacturing research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Merck & Co., Inc.7Pfizer Inc.